Association of patient characteristics and insurance type with anti‐obesity medications prescribing and fills
Authors:
Open Access
- 29 January 2024
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 26 (5) , 1687-1696
Abstract
Aim: To characterize factors associated with the receipt of anti‐obesity medication (AOM) prescription and fill. Materials and Methods: This retrospective cohort study used electronic health records from 1 January 2015 to 30 June 2023, in a large health system in Ohio and Florida. Adults with a body mass index ≥30 kg/m 2 who attended ≥1 weight‐management programme or had an initial AOM prescription between 1 July 2015 and 31 December 2022, were included. The main measures were a prescription for an AOM (naltrexone‐bupropion, orlistat, phentermine‐topiramate, liraglutide 3.0 mg and semaglutide 2.4 mg) and an AOM fill during the study follow‐up. Results: We identified 50 678 adults, with a mean body mass index of 38 ± 8 kg/m 2 and follow‐up of 4.7 ± 2.4 years. Only 8.0% of the cohort had AOM prescriptions and 4.4% had filled prescriptions. In the multivariable analyses, being a man, Black, Hispanic and other race/ethnicity (vs. White), Medicaid, traditional Medicare, Medicare Advantage, self‐pay and other insurance types (vs. private insurance) and fourth quartile of the area deprivation index (vs. first quartile) were associated with lower odds of a new prescription. Hispanic ethnicity, being a man, Medicaid, traditional Medicare and Medicare Advantage insurance types, liraglutide and orlistat (vs. naltrexone‐buproprion) were associated with lower odds of AOM fill, while phentermine‐topiramate was associated with higher odds. Among privately insured individuals, the insurance carrier was associated with both the odds of AOM prescription and fill. Conclusions: Significant disparities exist in access to AOM both at the prescribing stage and getting the prescription filled based on patient characteristics and insurance type.Keywords
Funding Information
- National Cancer Institute (1K99CA277136‐01)
This publication has 32 references indexed in Scilit:
- Making Neighborhood-Disadvantage Metrics Accessible — The Neighborhood AtlasNew England Journal of Medicine, 2018
- US health policy and prescription drug coverage of FDA-approved medications for the treatment of obesityInternational Journal of Obesity, 2017
- Weight loss drugs and lifestyle modification: Perceptions among a diverse adult samplePatient Education and Counseling, 2017
- Low adoption of weight loss medications: A comparison of prescribing patterns of antiobesity pharmacotherapies and SGLT2sObesity, 2016
- Estimating the Medical Care Costs of Obesity in the United States: Systematic Review, Meta-Analysis, and Empirical AnalysisValue in Health, 2016
- Why Summary Comorbidity Measures Such As the Charlson Comorbidity Index and Elixhauser Score WorkMedical Care, 2015
- Clinicians' Implicit Ethnic/Racial Bias and Perceptions of Care Among Black and Latino PatientsThe Annals of Family Medicine, 2013
- Implicit and Explicit Anti-Fat Bias among a Large Sample of Medical Doctors by BMI, Race/Ethnicity and GenderPLOS ONE, 2012
- Choosing Statistical TestsDeutsches Ärzteblatt international, 2010
- Availability of Recreational Resources in Minority and Low Socioeconomic Status AreasAmerican Journal of Preventive Medicine, 2008